Lexapro (escitalopram) and Zoloft (sertraline) are the two most commonly prescribed SSRIs for anxiety. Both are first-line treatments with similar overall efficacy in generalized anxiety. Lexapro is often slightly better tolerated in the first weeks; sertraline has stronger evidence in panic disorder and PTSD. The choice depends on the specific condition, the patient's history, and clinical fit.
The short version
For most patients with generalized anxiety, either medication is reasonable. Many psychiatrists default to one or the other based on personal experience; both have decades of safety data and similar response rates. For panic disorder, social anxiety, OCD, and PTSD, sertraline has slightly stronger evidence and is often preferred. For patients on multiple medications or for older adults, Lexapro's cleaner drug-interaction profile sometimes wins out. The class-level picture is covered in how CBT and SSRIs work.
How they differ
Approved indications
Lexapro (escitalopram) is FDA-approved for major depressive disorder and generalized anxiety disorder.
Zoloft (sertraline) is FDA-approved for major depressive disorder, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, social anxiety disorder, and premenstrual dysphoric disorder.
Sertraline carries more FDA-approved anxiety-related indications. Both are widely used off-label across the others. The MedlinePlus escitalopram page and the MedlinePlus sertraline page are good consumer-facing references.
Dosing
Lexapro: starting dose 5 to 10 mg, typical effective dose 10 to 20 mg, maximum 20 mg. One pill, once daily.
Zoloft: starting dose 25 mg, typical effective dose 50 to 200 mg, maximum 200 mg. Take with food to improve absorption and reduce GI side effects.
Side effects
The side effect profiles overlap substantially. Both can cause nausea and GI upset in the first two weeks, sleep changes, headache, sexual side effects that may persist, an initial uptick in anxiety, and discontinuation symptoms with abrupt stopping.
Specific differences observed in practice:
- Sertraline produces GI side effects (loose stools, indigestion) somewhat more often than escitalopram in the first weeks.
- Escitalopram produces slightly more dose-dependent QT prolongation, which becomes clinically relevant in patients on other QT-prolonging medications or with cardiac issues.
- Sexual side effects appear roughly equally on both.
Drug interactions
Escitalopram has a clean cytochrome P450 profile and few significant drug interactions. Sertraline has some CYP2D6 inhibition, which can affect levels of some beta-blockers, certain tricyclic antidepressants, some opioids, and tamoxifen. For older adults on polypharmacy, escitalopram is often the cleaner choice.
Use during pregnancy
Both have relatively reassuring pregnancy data among SSRIs. Sertraline has the most extensive data and is often preferred when an SSRI is started during pregnancy. The decision is always made with both a psychiatrist and an obstetrician.
Cost
Both are available as generics. Generic escitalopram and generic sertraline are inexpensive on most pharmacy plans. Brand-name Lexapro and Zoloft aren't typically necessary.
When to choose Lexapro
- Patient with generalized anxiety as the primary presentation
- Patient on multiple medications where drug interactions matter
- Older adult where a clean P450 profile matters
- Patient who tolerates GI side effects poorly
- Patient who prefers simpler dosing
When to choose Zoloft
- Patient with panic disorder, PTSD, social anxiety, or OCD as the primary presentation
- Patient who is pregnant or planning pregnancy
- Patient who has previously responded well to sertraline
What both have in common
- Four to six week therapeutic timeline at a stable dose
- FDA boxed warning on increased suicidal ideation in patients under 25 in the first weeks
- Discontinuation requires gradual taper
- Not controlled substances; no abuse potential
- Among non-responders to one, about 60% respond to the other
What if neither works
If a patient has tried both at adequate doses for six to eight weeks each without meaningful response, the next steps are typically a trial of an SNRI such as venlafaxine or duloxetine, augmentation with buspirone or mirtazapine, or reconsideration of the diagnosis. The NIMH anxiety disorders overview lays out the broader treatment landscape.
About 30 to 40 percent of patients don't respond meaningfully to the first SSRI tried. The pattern is well-described in the depression-treatment literature, including the STAR*D sequenced-treatment trial, and applies similarly in anxiety. Sequential trials of a different SSRI or a different class produce response in most patients who don't respond to the first medication. Sequential trials with appropriate dose and duration produce response in most patients eventually.